Unibest

Pharmaceutical intermediates

Olaparib Intermediates

5 pharmaceutical intermediates for Olaparib. Indication: Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Castration-resistant prostate cancer; Pancreatic cancer; Breast cancer; Endometrial cancer.

提交项目All intermediates

About Olaparib

Originator
Astrazeneca
Indication
Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Castration-resistant prostate cancer; Pancreatic cancer; Breast cancer; Endometrial cancer
Approved Date
12/19/2014
DS/DP
08/12/2027

Available intermediates

5 intermediates currently listed for Olaparib. Request specifications, documentation or a quotation for any item below.

Olaparib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Fluoro-5-formylbenzonitrile218301-22-5//
2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile763114-25-6//
2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid763114-26-7//
1-(Cyclopropylcarbonyl)piperazine hydrochloride1021298-67-8//
3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid61260-15-9//

Other programs under O

OfloxacinOliceridineOmadacycline toslateOrforglipronOSIMERTINIB MESYLATEOzenoxacin

Building toward Olaparib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →